NYSEAMERICAN:IGC IGC Pharma Q1 2026 Earnings Report $0.26 0.00 (-1.52%) Closing price 04:10 PM EasternExtended Trading$0.26 +0.00 (+0.77%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast IGC Pharma EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIGC Pharma Revenue ResultsActual Revenue$0.32 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIGC Pharma Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) IGC Pharma Earnings HeadlinesIGC Pharma Executives Convert Debt Into Equity SharesJuly 10, 2026 | theglobeandmail.comIGC Pharma, Inc.: IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative WorkflowJuly 9, 2026 | finanznachrichten.deThe Pentagon is desperateThe Pentagon has admitted the US trails Russia and China in hypersonic weapons, and its research budget has nearly tripled in five years. One small Florida company, trading under $5, is already under contract with Lockheed Martin, GE Aerospace, and the US Air Force to help test this technology at extreme altitudes. The company also launches commercial satellites and is nearing a major licensing milestone that could reshape its valuation.July 28 at 1:00 AM | Freedom Financial (Ad)IGC Pharma (NYSE: IGC) CEO discusses AI, Alzheimer's drug development and key 2026 catalysts on The Street podcastJuly 9, 2026 | msn.comIGC Pharma, Inc.: IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the CompanyJuly 7, 2026 | finanznachrichten.deICG Static on Alzheimer TestsJune 11, 2026 | baystreet.caSee More IGC Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email. Email Address About IGC PharmaIGC Pharma (NYSEAMERICAN:IGC), a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.View IGC Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Stocks Have Soared in 2026—Can They Keep Climbing?Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryRambus: Another AI Phoenix Ready to Rise From the Ashes of CorrectionAmkor Sells Off After Earnings—Why Weak Guidance Isn't the Real StoryWestern Digital’s Earnings Will Test Whether Its AI Rally Has More RoomIs the Market Mispricing ServiceNow's AI Future?Whirlpool’s Report May Show How Frozen the Housing Market Really Is Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
